The Serum Institute of India’s (SII) indigenously developed Quadrivalent Human Papillomavirus vaccine (qHPV) — Cervavac — was recently granted regulatory approval for sale by the Drugs Controller General of India (DGCI). It sets out to prevent cervical cancer — one of the leading causes of female cancer mortality in the […]